--- title: "Nurix Therapeutics (NRIX) news: offering" url: "https://aibio.space/companies/nurix-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NRIX offering news: Nurix Therapeutics lifts its at-the-market program total to $413.65 million. Nurix Therapeutics, Inc. (NASDAQ: NRIX), United States." --- NRIX Nurix Therapeutics, Inc. NASDAQ · United States # Nurix Therapeutics (NRIX) news NRIX offering news Financings · 2026-03-06 ## [Nurix Therapeutics lifts its at-the-market program total to $413.65 million](https://aibio.space/news/nurix-therapeutics-lifts-market-program-total-413-65-million/) Nurix raised its Piper Sandler at-the-market program to $413.65 million, of which $113.65 million has already been sold. Its fiscal 2025 net loss was $264.5 million and cash used in operations was $249.5 million. ## Latest Nurix Therapeutics news We have not published a story on Nurix Therapeutics yet. When there is news, it will appear here. ## Nurix Therapeutics at a glance - **Ticker**: NRIX - **Listing**: NASDAQ - **Country**: United States - **Cash, Aug 31, 2026**: $720.2 million ### Related companies - [Imunon](https://aibio.space/companies/imunon/) NASDAQ: IMNN - [SKYTECH ORION GLOBAL CORP.](https://aibio.space/companies/skytech-orion-global/) OTC: SKTG - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) NASDAQ: FBLG - [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) OTC: CARM - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics/) NASDAQ: IRLA - [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) NYSE: ANRO - [Editas Medicine](https://aibio.space/companies/editas-medicine/) NASDAQ: EDIT ### Also on NASDAQ - [Allogene Therapeutics](https://aibio.space/companies/allogene-therapeutics/) ALLO - [Sanara MedTech](https://aibio.space/companies/sanara-medtech/) SMTI - [Quanterix](https://aibio.space/companies/quanterix/) QTRX - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) CLRB - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) HRMY - [TherapeuticsMD](https://aibio.space/companies/therapeuticsmd/) TXMD ## What Nurix Therapeutics does Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for patients with cancer and inflammatory diseases. The company describes its DEL-AI discovery engine as an artificial intelligence-integrated platform that combines DNA encoded library hit-finding with ligase expertise. Its wholly owned clinical pipeline includes bexobrutideg (NX-5948), a highly selective degrader of Bruton's tyrosine kinase (BTK) in a Phase 2 study in relapsed or refractory chronic lymphocytic leukemia (CLL); zelebrudomide (NX-2127), a dual degrader of BTK and the IKZF1 and IKZF3 transcription factors in a Phase 1a/1b study in relapsed or refractory B-cell malignancies; and NX-1607, an inhibitor of the CBL-B E3 ligase in a Phase 1a/1b study across oncology indications. Its partnered pipeline includes a clinical-stage IRAK4 degrader (NX-0479/GS-6791) and a preclinical STAT6 degrader. The company names collaborations with Gilead Sciences, Sanofi and Pfizer, and the text says it had received $482.0 million in non-dilutive financing from its collaborators as of November 30, 2025. | Product or program | What it is | Stage | |---|---|---| | bexobrutideg | Oral selective BTK degrader for relapsed or refractory B-cell malignancies | Phase 2 | | zelebrudomide | Oral dual degrader of BTK and IKZF1 and IKZF3 | Phase 1a/1b | | NX-1607 | Oral CBL-B inhibitor for solid tumors and other oncology indications | Phase 1a/1b | Summarised from the company's [10-K filed Jan 28, 2026](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm). ## Nurix Therapeutics annual financials | Line | FY ended Nov 30, 2025 | FY ended Nov 30, 2024 | |---|---|---| | Research and development | [$316.9 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/) | [$221.6 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/) | | Net income (loss) | [-$264.5 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/) | [-$193.6 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/) | | Cash from operations | [-$249.5 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/) | [-$172.6 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/) | | Cash and equivalents | [$247.0 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/) | [$110.0 million](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/) | Latest balance sheet, Aug 31, 2026 (10-Q): cash and equivalents $720.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nurix Therapeutics Has Nurix Therapeutics raised money recently? Our latest story on this, dated Mar 6, 2026: "Nurix Therapeutics lifts its at-the-market program total to $413.65 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nurix-therapeutics-lifts-market-program-total-413-65-million/). What is the ticker symbol of Nurix Therapeutics? Nurix Therapeutics, Inc. trades under the ticker NRIX on NASDAQ. Where is Nurix Therapeutics listed? Nurix Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Nurix Therapeutics? The SEC Central Index Key (CIK) for Nurix Therapeutics, Inc. is 1549595. Its filings are on SEC EDGAR. How many shares does Nurix Therapeutics have outstanding? 109,249,814 shares as of 2026-09-30, per the cover page of its 10-Q filed 2026-10-13. Which country or territory is Nurix Therapeutics listed under? Our directory records Nurix Therapeutics, Inc. under United States. What does Nurix Therapeutics do? Our directory classifies Nurix Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Nurix Therapeutics? The ISIN recorded for Nurix Therapeutics, Inc. is US67080M1036. Does aibio.space cover Nurix Therapeutics? aibio.space lists Nurix Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Nurix Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Nurix Therapeutics develop? Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for patients with cancer and inflammatory diseases. The company describes its DEL-AI discovery engine as an artificial intelligence-integrated platform that combines DNA encoded library hit-finding with ligase expertise. What is bexobrutideg from Nurix Therapeutics? bexobrutideg: Oral selective BTK degrader for relapsed or refractory B-cell malignancies Stage: Phase 2. What is zelebrudomide from Nurix Therapeutics? zelebrudomide: Oral dual degrader of BTK and IKZF1 and IKZF3 Stage: Phase 1a/1b. Is Nurix Therapeutics profitable? Nurix Therapeutics, Inc. reported a net loss of $264.5 million for the fiscal year ended Nov 30, 2025, and used $249.5 million of cash in operations, per its annual report to the SEC. How much does Nurix Therapeutics spend on research and development? $316.9 million in the fiscal year ended Nov 30, 2025, per its annual report. ## Investor discussion: Nurix Therapeutics Members talk about Nurix Therapeutics (NRIX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nurix Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1549595/000119312526096717/d96244d424b5.htm) 2. 2025-10-22 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1549595/000119312525246964/d46133dex991.htm) 3. 2024-10-31 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1549595/000119312524248678/d904494d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NRIX on TradingView](https://www.tradingview.com/symbols/NASDAQ-NRIX/). ## SEC filings and registration - **SEC name**: Nurix Therapeutics, Inc. - **CIK**: 1549595 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NRIX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: November 30 - **Filer category**: Large accelerated filer - **Business address**: 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005 - **Phone**: (415) 660-5320 - **Shares outstanding**: 109,249,814 as of 2026-09-30 (10-Q filed 2026-10-13) - **Former names**: Nurix, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261012.htm) filed 2026-10-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000040/nrix-20260531.htm) filed 2026-07-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/nrix-20260709.htm) filed 2026-07-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/nrix-20260611.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/nrix-20260606.htm) filed 2026-06-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000028/nrix-20260515.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000025/nrix-20260228.htm) filed 2026-04-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001549595), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Nurix Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NRIX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nurix Therapeutics, Inc. - **Ticker**: NRIX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US67080M1036 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NRIX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nurix-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nurix Therapeutics (NRIX) news: offering", 2026-10-31, https://aibio.space/companies/nurix-therapeutics/